Crohn's disease
Gastroenterology · 2007–2026
44decisions
10medicines
29carried consumer input
233individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| upadacitinib Complex refractory fistulising Crohn's disease with externally draining enterocutaneous or rectovaginal fistula. | Mar 2026 | Recommended with restriction | no section in document |
| adalimumab Treatment of immune-mediated inflammatory diseases (IMIDs) in paediatric patients under 18 years of age, with disease severity considered sufficient to cause… | Jul 2025 | Recommended with restriction | 6 individuals |
| guselkumab Treatment of adults with severe Crohn's disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a… | Jul 2025 | Recommended with restriction | 1 individuals Colitis Australia |
| infliximab Multiple indications including rheumatoid arthritis, psoriatic arthritis, Crohn's disease in adults and children (6 to 17 years), refractory Crohn's disease,… | Jul 2025 | Recommended with restriction | input received Colitis Australia |
| infliximab Biosimilar to Remicade for rheumatoid arthritis, psoriatic arthritis, Crohn's disease (adults and children 6-17 years), refractory Crohn's disease, ankylosing… | Mar 2025 | Recommended with restriction | input received |
| infliximab Amendment to restriction level for continuing treatment of severe active rheumatoid arthritis, severe Crohn disease, severe chronic plaque psoriasis, severe… | Mar 2025 | Recommended with restriction | input received |
| ustekinumab Severe chronic plaque psoriasis, severe psoriatic arthritis, severe Crohn disease, complex refractory fistulising Crohn disease, and moderate to severe… | Mar 2025 | Recommended with restriction | input received |
| vedolizumab Dose escalation from 8-weekly to 4-weekly intravenous maintenance treatment in adults with moderate to severe ulcerative colitis or severe Crohn disease who… | Nov 2025 | Not recommended | input received Colitis Australia |
| budesonide Treatment of mild to moderately active Crohn disease affecting the ileum and/or the ascending colon. | Mar 2024 | Recommended | input received Colitis Australia |
| ustekinumab Treatment of paediatric severe chronic plaque psoriasis, severe Crohn disease, moderate to severe ulcerative colitis, and complex refractory fistulising Crohn… | Mar 2024 | Recommended | input received Colitis Australia |
| vedolizumab Additional induction dose (week 10) for severe Crohn disease in patients who have not responded to the standard three-dose induction therapy (weeks 0, 2, 6). | Mar 2024 | Recommended | input received Colitis Australia |
| ustekinumab Severe chronic plaque psoriasis (adult and paediatric), severe psoriatic arthritis, severe Crohn disease, and complex refractory fistulising Crohn disease. | Nov 2024 | Recommended | input received Colitis Australia |
| upadacitinib Treatment of severe Crohn disease in adults who have failed to achieve an adequate response, or are contraindicated, to prior systemic therapy. | Jul 2023 | Recommended with restriction | input received Colitis Australia |
| ustekinumab Complex refractory fistulising Crohn disease in adult patients. | Jul 2023 | Recommended with restriction | input received Colitis Australia |
| risankizumab Severe Crohn's disease in adults who have failed to achieve an adequate response or are contraindicated to prior systemic therapy; Complex refractory… | Jul 2022 | Recommended with restriction | input received Colitis Australia |
| ustekinumab Treatment of patients with Crohn disease and severe chronic plaque psoriasis requiring a 90 mg dose of ustekinumab, in a pre-filled syringe formulation. | Jul 2022 | Recommended | none received |
| infliximab Treatment of ankylosing spondylitis, severe chronic plaque psoriasis, severe active psoriatic arthritis, and complex refractory fistulising Crohn's disease via… | Mar 2022 | Recommended with restriction | unclear |
| adalimumab Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, hidradenitis suppurativa, chronic plaque psoriasis, ulcerative colitis, Crohn's disease, and… | Nov 2022 | Not recommended | 1 individuals |
| mesalazine Management of an acute episode of mild to moderate ulcerative proctitis (suppository); ulcerative colitis and Crohn disease (modified release granules). | Mar 2020 | Recommended | 1 individuals |
| protein formula with carbohydrate, fat, vitamins, minerals and transforming growth factor beta-2 Dietary management of Crohn disease in the active or remission phases in adults and children over the age of 5 years, as enteral nutrition. | Mar 2020 | Not recommended | input received Colitis Australia · Israel Medical Association |
| infliximab Treatment of adults with severe active rheumatoid arthritis, ankylosing spondylitis, severe refractory Crohn's disease, complex refractory fistulising Crohn's… | Nov 2020 | Recommended with restriction | input received Colitis Australia · Parallel- Group |
| vedolizumab Maintenance treatment for patients with moderate to severe ulcerative colitis (MSUC) and severe Crohn's disease (CD) who have responded to intravenous… | Nov 2020 | Recommended with restriction | input received Colitis Australia |
| budesonide Treatment of mild to moderate Crohn's disease affecting the ileum and/or the ascending colon. | Mar 2019 | Recommended | 1 individuals |
| budesonide Treatment of patients with mild to moderate Crohn's disease affecting the ileum and/or ascending colon. | Mar 2019 | Recommended with restriction | 2 individuals |
| infliximab Subsequent continuing treatment for severe Crohn disease, complex refractory fistulising Crohn disease, moderate to severe Crohn disease, moderate to severe… | Mar 2019 | Recommended with restriction | 3 individuals |
| adalimumab Severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, juvenile idiopathic arthritis, severe… | Jul 2018 | Recommended | 1 individuals |
| adalimumab Multiple indications including severe Crohn's disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, fistulising Crohn's… | Jul 2018 | Recommended with restriction | none received |
| budesonide Treatment of mild to moderate Crohn's disease affecting the ileum and/or the ascending colon. | Jul 2018 | Recommended | input received |
| mesalazine Treatment of ulcerative colitis and Crohn disease in patients with documented hypersensitivity reaction to sulphonamides or intolerance to sulfasalazine. | Jul 2018 | Recommended with restriction | none received |
| ustekinumab Severe Crohn's disease and complex refractory fistulising Crohn's disease in adults aged 18 years or older who have failed conventional therapies. | Mar 2017 | Recommended | 41 individuals |
| infliximab Change to initial and continuing treatment restrictions for the biosimilar brand of infliximab (Renflexis) for severe active rheumatoid arthritis, ankylosing… | Nov 2017 | Recommended with restriction | none received |
| budesonide Treatment of mild to moderate Crohn's disease affecting the ileum and/or the ascending colon. | Nov 2017 | Not recommended | 46 individuals |
| infliximab Biosimilar to Remicade for multiple indications including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, ulcerative colitis, and… | Nov 2016 | Recommended | none received |
| infliximab Biosimilar to Remicade for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, ulcerative colitis, and Crohn's disease. | Jul 2015 | Recommended with restriction | 2 individuals |
| vedolizumab Treatment of moderate to severe Crohn's disease in patients who have had an inadequate response with, lost response to, or are intolerant to either… | Mar 2015 | Recommended with restriction | 98 individuals |
| adalimumab Treatment of severe refractory Crohn's disease in paediatric patients aged 6 to 17 years. | Nov 2014 | Recommended with restriction | 30 individuals |
| infliximab complex refractory fistulising Crohn disease with a draining enterocutaneous or rectovaginal fistula | Mar 2010 | Recommended with restriction | no section in document |
| infliximab Complex fistulising Crohn disease with a draining enterocutaneous or rectovaginal fistula. | Mar 2010 | Recommended with restriction | no section in document |
| adalimumab treatment of complex refractory fistulising Crohn disease with a draining enterocutaneous or rectovaginal fistula | Nov 2010 | Recommended with restriction | unclear |
| Infliximab treatment of refractory moderate to severe Crohn’s disease in paediatric patients (aged 6-17 years inclusive) | Jul 2007 | Recommended with restriction | no section in document |
| infliximab Treatment of moderate to severe Crohn's disease in paediatric patients aged 6-17 years who are refractory to conventional therapies. | Jul 2007 | Recommended with restriction | no section in document |
| Infliximab Treatment of severe Crohn’s disease in adults who have an inadequate response to conventional therapies, and for patients with an ileostomy or colectomy due to… | Mar 2007 | Recommended with restriction | no section in document |
| adalimumab Treatment of patients with moderate to severe Crohn disease (CDAI > 300) or patients with an ileostomy or colectomy due to Crohn disease who have inadequate… | Nov 2007 | Recommended with restriction | no section in document |
| adalimumab Treatment of patients with moderate to severe Crohn disease (CDAI > 300) or in patients with an ileostomy or colectomy due to Crohn disease. | Nov 2007 | Recommended with restriction | no section in document |
Who spoke
Colitis Australia · Parallel- Group · Israel Medical Association
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 29 of 36 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.